Search
Results: 9
ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers
Carmel M McEniery, Marie Fisk, Karen Miles, Fotini Kaloyirou, Annette Hubsch, Jane Smith, Ian B Wilkinson, Joseph Cheriyan
Jul 06, 2020
OBJECTIVES: PRIMARY OBJECTIVE: To determine whether chemoprophylaxis with hydroxychloroquine versus placebo increases time to contracting coronavirus disease 2019 (COVID-19) in frontline healthcare workers. SECONDARY OBJECTIVES...
covid-19 Chemoprophylaxis Daily-dosing Healthcare workers Hydroxychloroquine placebo Protocol randomised controlled trial Weekly-dosing Adolescent Adult Aged Antiviral Agents Betacoronavirus covid-19 COVID-19 Testing Chemoprevention Clinical Laboratory Techniques Coronavirus Infections Drug Administration Schedule England Female Health Personnel Host-Pathogen Interactions Humans Hydroxychloroquine Male Medication Adherence Middle Aged Occupational health Pandemics Pneumonia Viral Protective factors Randomized Controlled Trials as Topic Remission Induction Risk Assessment Risk Factors SARS-CoV-2 Severity of Illness Index Time Factors Treatment Outcome Young Adult COVID-19 Drug Treatment
Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS)
Tian Xiao Zhao, Michalis Kostapanos, Charmaine Griffiths, Emma L Arbon, Annette Hubsch, Fotini Kaloyirou, Joanna Helmy, Stephen P Hoole, James HF Rudd, Graham Wood, Keith Burling, Simon Bond, Joseph Cheriyan, Ziad Mallat
Nov 07, 2018
INTRODUCTION: Inflammation and dysregulated immune responses play a crucial role in atherosclerosis, underlying ischaemic heart disease (IHD) and acute coronary syndromes (ACSs). Immune responses are also major determinants of...
Acute Coronary Syndrome aldesleukin interleukin 2 ischaemic heart disease Regulatory T cells Acute Coronary Syndrome C-Reactive Protein Clinical Trials Phase I as Topic Clinical Trials Phase II as Topic Double-Blind Method Humans Immunologic Factors Interleukin-2 Interleukin-6 Lymphocyte Count Myocardial Ischemia Natriuretic Peptide Brain Randomized Controlled Trials as Topic Recombinant Proteins T-Lymphocytes Regulatory Troponin
Investigation of the associations between physical activity, self-regulation and educational outcomes in childhood.
It is common knowledge that physical activity leads to physiological and psychological benefits. The current study explored the association between physical activity and self-regulation longitudinally and the indirect...
Published by: PLOS ONE
Investigation of the associations between physical activity, self-regulation and educational outcomes in childhood
It is common knowledge that physical activity leads to physiological and psychological benefits. The current study explored the association between physical activity and self-regulation longitudinally and the indirect...
Investigation of the associations between physical activity, self-regulation and educational outcomes in childhood.
It is common knowledge that physical activity leads to physiological and psychological benefits. The current study explored the association between physical activity and self-regulation longitudinally and the indirect...
Comparisons of Staphylococcus aureus infection and other outcomes between users of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers
Patrick Bidulka, Masao Iwagami, Kathryn E Mansfield, Fotini Kalogirou, Angel YS Wong, Ian J Douglas, Liam Smeeth, Charlotte Summers, Laurie A Tomlinson
May 20, 2020
Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes
Patrick Bidulka, Edouard L Fu, Clémence Leyrat, Fotini Kalogirou, Katherine SL McAllister, Edward J Kingdon, Kathryn E Mansfield, Masao Iwagami, Liam Smeeth, Catherine M Clase, Krishnan Bhaskaran, Merel van Diepen, Juan-Jesus Carrero, Dorothea Nitsch, Laurie A Tomlinson
Jul 29, 2021
BACKGROUND: The safety of restarting angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) after acute kidney injury (AKI) is unclear. There is concern that previous users do not restart...
Acute Kidney Injury Angiotensin II receptor blocker (ARB) Angiotensin-converting enzyme inhibitor (ACEI) Heart Failure Acute Kidney Injury Adolescent Adult Aged Aged 80 and over Angiotensin Receptor Antagonists Angiotensin-Converting Enzyme Inhibitors Cohort Studies Female Humans Male Middle Aged Proportional Hazards Models Sweden United Kingdom Young Adult
Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes
Patrick Bidulka, Edouard L. Fu, Clémence Leyrat, Fotini Kalogirou, Katherine S. L. McAllister, Edward J. Kingdon, Kathryn E. Mansfield, Masao Iwagami, Liam Smeeth, Catherine M. Clase, Krishnan Bhaskaran, Merel van Diepen, Juan-Jesus Carrero, Dorothea Nitsch, Laurie A. Tomlinson
Jul 29, 2020
Abstract: Background: The safety of restarting angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) after acute kidney injury (AKI) is unclear. There is concern that previous users do not...